Protection against 3,4-methylenedioxymethamphetamine-induced neurodegeneration produced by glutathione depletion in rats is mediated by attenuation of hyperthermia

Journal of Neurochemistry

Volumn 81, Issue 4, 2002, Pages 686-695

  O'Shea, E ^a,c   Easton, N ^a   Fry, J R ^a   Green, A R ^b   Marsden, C A ^a  

^a QUEEN S MEDICAL CENTRE   (United Kingdom)

^b DE MONTFORT UNIVERSITY   (United Kingdom)

^c UNIVERSIDAD COMPLUTENSE DE MADRID   (Spain)

Author keywords

3,4 methylenedioxymethamphetamine; Glutathione; Hyperthermia; Metabolite; Neuroprotection; Neurotoxicity

Indexed keywords

3,4 METHYLENEDIOXYMETHAMPHETAMINE; BUTHIONINE SULFOXIMINE; GLUTATHIONE; PAROXETINE; SEROTONIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; ATTENUATION; BRAIN TISSUE; DRUG EFFECT; DRUG MECHANISM; DRUG METABOLISM; HYPERTHERMIA; MALE; NERVE DEGENERATION; NEUROPROTECTION; NEUROTOXICITY; NONHUMAN; PRIORITY JOURNAL; RAT; RAT STRAIN; SEROTONINERGIC NERVE;

ANIMALS; BRAIN; BRAIN CHEMISTRY; BUTHIONINE SULFOXIMINE; DRUG THERAPY, COMBINATION; FEVER; GLUTATHIONE; HYDROXYINDOLEACETIC ACID; LIVER; MALE; MALEATES; N-METHYL-3,4-METHYLENEDIOXYAMPHETAMINE; NEURODEGENERATIVE DISEASES; PAROXETINE; RATS; RATS, INBRED STRAINS; SEROTONIN; TREATMENT OUTCOME;

AGOUTI; ANIMALIA;

EID: 0036316571     PISSN: 00223042     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1471-4159.2002.00844.x     Document Type: Article

References (61)

1. Serotonergic neurotoxicity of 3,4-(±)-methylenedioxyamphetamine and 3,4-(±)-methylenedioxymethamphetamine (Ecstasy) is potentiated by inhibition of γ-glutamyl transpeptidase
2. Glutathione and N-acetyl-cysteine conjugates of alpha-methyldopamine produce serotonergic neurotoxicity: Possible role in methylenedioxyamphetamine-mediated neurotoxicity
3. MDMA-induced neurotoxicity: Parameters of degeneration and recovery of brain serotonin neurons
4. 3,4-Methylenedioxymethamphetamine and 3,4-methylenedioxyamphetamine destroy serotonin terminals in rat brain: Quantification of neurodegeneration by measurement of [3H]paroxetine-labeled serotonin uptake sites
5. Sympathetic inhibition of thermogenesis in the infant rat: Possible glucostatic control
6. Enzyme-catalysed conjugations of glutathione with unsaturated compounds
7. Multiple severe complications from recreational ingestion of MDMA ('Ecstasy')
8. Stereochemical differences in the metabolism of 3,4-methylenedioxymethamphetamine in vivo and in vitro: A pharmacokinetic analysis
9. The spin trap reagent alpha-phenyl-N-tert-butyl nitrone prevents 'ecstasy'-induced neurodegeneration of 5-hydroxytryptamine neurones
10. Studies on the neuroprotective effect of pentobarbitone on MDMA-induced neurodegeneration
11. Role of hyperthermia in the protective action of clomethiazole against MDMA ('ecstasy')-induced neurodegeneration, comparison with the novel NMDA channel blocker AR-R15896AR
12. Studies on the role of dopamine in the degeneration of 5-HT nerve endings in the brain of Dark Agouti rats following 3,4-methylenedioxymethamphetamine (MDMA or 'ecstasy') administration
13. A study of the neurotoxic effect of 'ecstasy' (MDMA) on 5-HT neurones in the brains of mothers and neonates following administration of the drug during pregnancy
14. In vivo evidence for free radical involvement in the degeneration of rat brain 5-HT neurones which follows administration of MDMA ('ecstasy'); but not the degeneration which follows fenfluramine
15. Biochemical and histological evidence that methylenedioxymethylamphetamine (MDMA) is toxic to neurons in the rat brain
16. Effect of diethylmaleate and other glutathione depletors on protein synthesis
17. 'Eve' and 'Ecstasy'. A report of five deaths associated with the use of MDEA and MDMA
18. Glutathione depletion and resynthesis in laboratory animals
19. Long-term alteration in the central monoammergic systems of the rat by 2,4,5-trihydroxyamphetamine but not by 2-hydroxy-4,5-methylenedioxymethamphetamine or 2-hydroxy-4,5-methylenedioxyamphetamine
20. 3,4-Methylenedioxymethamphetamine induces monoamine release, but not toxicity, when administered centrally at a concentration occurring following a peripherally injected neurotoxic dose
21. Role of hypothermia in the mechanism of protection against serotonergic toxicity. I. Experiments using 3,4-methylenedioxymethamphetamine, dizocilpine, CGS 19755 and NBQX
22. Role of hypothermia in the mechanism of protection against serotonergic toxicity. II. Experiments with methamphetamine, p-chloroamphetamine, fenfluramine, dizocilpine and dextromethorphan
23. Orally administered MDMA causes a long-term depletion of serotonin in rat brain
24. Review of the pharmacology and clinical pharmacology of 3,4-methylenedioxymethamphetamine (MDMA or 'Ecstasy')
25. Potent and specific inhibition of glutathione synthesis by buthionine sulfoximine (S-n-butyl homocysteine sulfoximine)
26. Glutathione: Interorgan translocation, turnover, and metabolism
27. Origin and turnover of mitochondrial glutathione
28. Altered serotonin innervation patterns in the forebrain of monkeys treated with (±) 3,4-methylenedioxymethamphetamine seven years previously: Factors influencing abnormal recovery
29. Ecstasy and the dance of death
30. Chlormethiazole, dizocilpine and haloperidol prevent the degeneration of serotonergic nerve terminals induced by administration of MDMA ('Ecstasy') to rats
31. Metabolism of methylenedioxymethamphetamine: Formation of dihydroxymethamphetamine and a quinone identified as its glutathione adduct
32. Effects of 3,4-dihydroxymethamphetamine and 2,4,5-trihydroxymethamphetamine, two metabolites of 3,4-methylenedioxymethamphetamine, on central serotonergic and dopaminergic systems
33. Interference of chemicals with glycogen metabolism in isolated hepatocytes
34. In vivo and in vitro metabolism of 3,4-(methylenedioxy) methamphetamine in the rat: Identification of metabolite using an ion trap detector
35. In vivo formation of aromatic hydroxylated metabolites of 3,4-(methylenedioxy)-methamphetamine in the rat: Identification by ion trap ms/ms and ms/ms/ms techniques
36. Ion trap tandem mass spectrometric evidence for the metabolism of 3,4-(methylenedioxy) methamphetamine to the potent neurotoxin 2,4,5-trihydroxymethamphetamine and 2,4,5-trihydroxyamphetamine
37. Enzymatic and chemical demethylation of (methylenedioxy) amphetamine and (methylenedioxy) methamphetamine by rat brain microsomes
38. Protein measurement with the Folin phenol reagent
39. Major metabolites of (±) 3,4-methylenedioxyamphetamine (MDA) do not mediate its toxic effects on brain serotonin neurons
40. Altered neuroendocrine and behavioral responses to m-chlorophenylpiperazine in 3,4-methylenedioxymethamphetamine (MDMA) users
41. Neurotoxic effects in human brains after use of 3,4-methylenedioxymethamphetamine ('Ecstasy') viewed by positron emission tomography
42. Co-administration of MDMA with drugs that protect against MDMA neurotoxicity produces different effects on body temperature in the rat
43. Metabolism of 5-(glutathion-S-yl)-α-methyldopamine following intracerebroventricular administration to male Sprague-Dawley rats
44. Effects of intracerebro-ventricular administration of 5-(glutathion-S-yl)-α-methyldopamine on brain dopamine, serotonin, and norepinephrine concentrations in male Sprague-Dawley rats
45. 2,5-bis-(glutathion-S-yl)-α-methyldopamine, a putative metabolite of (±)-3,4-methylenedioxymethamphetamine, decreases brain serotonin concentrations
46. Neurotoxicity of MDMA and related compounds: Anatomic studies
47. Modulation of glutathione conjugation in vivo: How to decrease glutathione conjugation in vivo or in intact cellular systems in vitro
48. Enhancement of 3,4-methylenedioxymethamphetamine neurotoxicity by the energy inhibitor malonate
49. Depletion of glutathione in normal and malignant human cells in vivo by buthionine: Clinical and biochemical results
50. Methylenedioxyamphetamine (MDA) and methylenedioxymethamphetamine (MDMA) cause selective ablation of serotonergic axon terminals in forebrain: Immunocytochemical evidence for neurotoxicity
51. The relationship between the degree of neurodegeneration of rat brain 5-HT nerve terminals and the dose and frequency of administration of MDMA ('ecstasy')
52. Lack of serotonin neurotoxicity after intraraphe microinjection of (±) 3,4-methylenedioxymethamphetamine MDMA)
53. Brain uptake of S-(1,2-dichlorovinyl) glutathione and S-(1,2-dichlorovinyl)-L-cysteine, the glutathione and cysteine S-conjugates of the neurotoxin dichloroacetylene
54. Relationship between glutathione content in liver and glutathione conjugation rate in the rat in vivo. Effect of buthionine sulphoximine pre-treatment on conjugation of the two 2-bromoisovalerylurea enantiomers during intravenous infusion
55. Evaluation of hepatic toxicity of seven-day repeated-dose glutathione-depleting regimens in rats
56. Paradoxical effects of cobaltous chloride and salts of other divalent metals on tissue levels of reduced glutathione and microsomal mixed-function oxidase components
57. Neurotoxicity of MDMA: Neurochemical effects
58. Neurochemical and neurohistological alterations in the rat and monkey produced by orally administered methylenedioxymethamphetamine (MDMA)
59. Glucocorticoids and hypothermic induction and survival in the rat
60. The effects of 3,4-methylenedioxymethamphetamine (MDMA) and 3,4-methylenedioxyamphetamine (MDA) on monoaminergic systems in the rat brain
61. 'Ecstasy' and sudden cardiac death